

The 11th Annual
INNOVATOR
of the YEAR AWARDS



2025
KEYNOTE SPEAKER

RAYMOND W. COHEN

Co-Founder, Former CEO &
Board Member
Axonics, Inc.

Raymond W. Cohen is an accredited public company director who has served as the co-founder, CEO and member of the board of directors of Axonics, Inc., (Nasdaq: AXNX) a medical device company with implantable technologies to treat bladder and bowel disorders from inception in 2013 until November 2024, when Axonics was acquired by Boston Scientific Corp for \$3.7 billion.

Cohen was voted to receive the 2024 MedTech MVP Award at the 23rd Annual MedTech conference in June 2024. In January 2024, Cohen was named the Businessperson of the Year by the Orange County Business Journal. In late 2021, Cohen received a lifetime achievement award from SoCal Bio for his four decades of work in medical technology. In October 2020, Cohen was named as Entrepreneur of the Year by Ernst & Young for the Southwest US.

In 2021, Axonics was ranked on Deloitte's Technology Fast 500 and Financial Times listing as the #1 fastest growing company in America based on growth of 87,000 percent from 2017 to 2020, #4 based on 2018-2021 and #24 based on 2019-2022. In 2023, in only its fourth year of commercial activity, Axonics generated \$366 million in revenue at a 75% gross margin and generated nearly \$50 million in positive adjusted EBITDA.

Cohen currently serves as a venture advisor to Andera Partners based in Paris. Since 2023, Cohen also serves as an independent director for SoniVie, Ltd., a venture backed Israeli-based company developing a device treatment for hypertension and Kestra Medical Technologies, Inc., a privately held commercial stage wearable medical device company focused on development, manufacture and distribution of a wearable defibrillator.

For 15 years until 2021, Cohen served as Chairman of BioLife Solutions Inc. (Nasdaq: BLFS). Previously, Cohen served on the boards of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI), Zurich-based LifeWatch (LIFE.SW) which was acquired by BioTelemetry (Nasdaq: BEAT) and privately held Synchroness, Inc. sold to ALTEN Group, a French multi-billion-dollar engineering services company.

From 2010 to 2012, Cohen served as the CEO of Vessix Vascular, Inc., a device developer which was acquired by Boston Scientific Corp. in late 2012. Prior, Cohen was CEO of Nasdaq-listed, Cardiac Science, Inc., ranked by Deloitte as the 4th fastest growing company in North America in 2004. In his career, Cohen has been directly responsible for raising ~\$2 billion in capital.

Cohen holds a B.S. in Business Management from Binghamton University in NY.